传统中医手法治疗颈源性头晕的安全性和有效性:随机对照多中心试验研究方案

IF 1.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Yunfan Zhan , Yujie Zhang , Kaoqiang Liu , Ye Zhao , Jiawei Ning , Yongli Chai , Lingjun Kong , Weian Yuan
{"title":"传统中医手法治疗颈源性头晕的安全性和有效性:随机对照多中心试验研究方案","authors":"Yunfan Zhan ,&nbsp;Yujie Zhang ,&nbsp;Kaoqiang Liu ,&nbsp;Ye Zhao ,&nbsp;Jiawei Ning ,&nbsp;Yongli Chai ,&nbsp;Lingjun Kong ,&nbsp;Weian Yuan","doi":"10.1016/j.conctc.2024.101349","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cervicogenic dizziness is a clinical syndrome characterized by neck pain and dizziness, which has a rising incidence in recent years. In China, manual therapy has been widely used in the treatment of cervicogenic dizziness, but there is no high-quality medical evidence to support its effectiveness and safety. The purpose of this study was to assess the safety and efficacy of Shi's manual therapy (SMT) on the treatment of cervicogenic dizziness.</p></div><div><h3>Methods</h3><p>A multicenter randomized controlled trial (RCT) will perform on 106 patients (18≤ages≤65) who meet the diagnostic criteria of cervicogenic dizziness. Patients will be randomly allocated to the intervention group and the control group at a ratio of 1:1. Participants in the control group will be treated with Merislon (Betahistine Mesilate Tablets). Participants in the intervention group will be treated with SMT. The primary outcome is the response rate at week 2, which is defined as the proportion of patients who reduce their disability level measured by the Dizziness Handicap Inventory (DHI) score relative to baseline. Key secondary outcomes include DHI scores at weeks 1, 2, and 6 and changes from baseline, time to disappearance of dizziness symptoms, and recurrence rate of dizziness symptoms. Safety will be assessed by adverse events, physical examination and vital signs.</p></div><div><h3>Discussion</h3><p>This trial aims to provide high-quality evidence-based medical data to demonstrate that SMT can reduce dizziness in patients with cervicogenic dizziness effectively and safely.</p></div><div><h3>Trial registration</h3><p>Clinical Trial Registration Center NCT05604937. Registered on Nov 3, 2022.</p></div><div><h3>Protocol version</h3><p>1.0, November 20, 2022.</p></div>","PeriodicalId":37937,"journal":{"name":"Contemporary Clinical Trials Communications","volume":"41 ","pages":"Article 101349"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2451865424000966/pdfft?md5=0746cb8292b1b0a677d7c51adf67a5b1&pid=1-s2.0-S2451865424000966-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of traditional Chinese manual therapy for cervicogenic dizziness: study protocol for a randomized, controlled, multicenter trial\",\"authors\":\"Yunfan Zhan ,&nbsp;Yujie Zhang ,&nbsp;Kaoqiang Liu ,&nbsp;Ye Zhao ,&nbsp;Jiawei Ning ,&nbsp;Yongli Chai ,&nbsp;Lingjun Kong ,&nbsp;Weian Yuan\",\"doi\":\"10.1016/j.conctc.2024.101349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Cervicogenic dizziness is a clinical syndrome characterized by neck pain and dizziness, which has a rising incidence in recent years. In China, manual therapy has been widely used in the treatment of cervicogenic dizziness, but there is no high-quality medical evidence to support its effectiveness and safety. The purpose of this study was to assess the safety and efficacy of Shi's manual therapy (SMT) on the treatment of cervicogenic dizziness.</p></div><div><h3>Methods</h3><p>A multicenter randomized controlled trial (RCT) will perform on 106 patients (18≤ages≤65) who meet the diagnostic criteria of cervicogenic dizziness. Patients will be randomly allocated to the intervention group and the control group at a ratio of 1:1. Participants in the control group will be treated with Merislon (Betahistine Mesilate Tablets). Participants in the intervention group will be treated with SMT. The primary outcome is the response rate at week 2, which is defined as the proportion of patients who reduce their disability level measured by the Dizziness Handicap Inventory (DHI) score relative to baseline. Key secondary outcomes include DHI scores at weeks 1, 2, and 6 and changes from baseline, time to disappearance of dizziness symptoms, and recurrence rate of dizziness symptoms. Safety will be assessed by adverse events, physical examination and vital signs.</p></div><div><h3>Discussion</h3><p>This trial aims to provide high-quality evidence-based medical data to demonstrate that SMT can reduce dizziness in patients with cervicogenic dizziness effectively and safely.</p></div><div><h3>Trial registration</h3><p>Clinical Trial Registration Center NCT05604937. Registered on Nov 3, 2022.</p></div><div><h3>Protocol version</h3><p>1.0, November 20, 2022.</p></div>\",\"PeriodicalId\":37937,\"journal\":{\"name\":\"Contemporary Clinical Trials Communications\",\"volume\":\"41 \",\"pages\":\"Article 101349\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2451865424000966/pdfft?md5=0746cb8292b1b0a677d7c51adf67a5b1&pid=1-s2.0-S2451865424000966-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Contemporary Clinical Trials Communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2451865424000966\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Clinical Trials Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451865424000966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景颈源性头晕是一种以颈部疼痛和头晕为特征的临床综合征,近年来发病率呈上升趋势。在中国,手法治疗已被广泛用于颈源性头晕的治疗,但目前尚无高质量的医学证据支持其有效性和安全性。本研究的目的是评估施氏手法疗法(SMT)治疗颈源性头晕的安全性和有效性。方法将对106名符合颈源性头晕诊断标准的患者(18≤年龄≤65岁)进行多中心随机对照试验(RCT)。患者将按 1:1 的比例随机分配到干预组和对照组。对照组患者将接受美利曲隆(甲磺酸倍他司汀片)治疗。干预组的参与者将接受 SMT 治疗。主要结果是第 2 周的应答率,即通过头晕障碍量表 (DHI) 评分衡量的残疾程度相对于基线有所减轻的患者比例。主要次要结果包括第 1、2 和 6 周的 DHI 评分以及与基线相比的变化、头晕症状消失时间和头晕症状复发率。安全性将通过不良事件、体格检查和生命体征进行评估。讨论本试验旨在提供高质量的循证医学数据,证明SMT能有效、安全地减轻颈源性头晕患者的头晕症状。注册日期:2022年11月3日。协议版本1.0,2022年11月20日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety and efficacy of traditional Chinese manual therapy for cervicogenic dizziness: study protocol for a randomized, controlled, multicenter trial

Background

Cervicogenic dizziness is a clinical syndrome characterized by neck pain and dizziness, which has a rising incidence in recent years. In China, manual therapy has been widely used in the treatment of cervicogenic dizziness, but there is no high-quality medical evidence to support its effectiveness and safety. The purpose of this study was to assess the safety and efficacy of Shi's manual therapy (SMT) on the treatment of cervicogenic dizziness.

Methods

A multicenter randomized controlled trial (RCT) will perform on 106 patients (18≤ages≤65) who meet the diagnostic criteria of cervicogenic dizziness. Patients will be randomly allocated to the intervention group and the control group at a ratio of 1:1. Participants in the control group will be treated with Merislon (Betahistine Mesilate Tablets). Participants in the intervention group will be treated with SMT. The primary outcome is the response rate at week 2, which is defined as the proportion of patients who reduce their disability level measured by the Dizziness Handicap Inventory (DHI) score relative to baseline. Key secondary outcomes include DHI scores at weeks 1, 2, and 6 and changes from baseline, time to disappearance of dizziness symptoms, and recurrence rate of dizziness symptoms. Safety will be assessed by adverse events, physical examination and vital signs.

Discussion

This trial aims to provide high-quality evidence-based medical data to demonstrate that SMT can reduce dizziness in patients with cervicogenic dizziness effectively and safely.

Trial registration

Clinical Trial Registration Center NCT05604937. Registered on Nov 3, 2022.

Protocol version

1.0, November 20, 2022.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
2.70
自引率
6.70%
发文量
146
审稿时长
20 weeks
期刊介绍: Contemporary Clinical Trials Communications is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信